TRELSTAR - Prostate Cancer Facts

Following are some facts interesting to know about prostate cancer:

It is the second most common cancer discovered in American men. Skin cancer is number one.
Cancer of the prostate is the third leading cause of cancer death in men. This is exceeded only by lung cancer and colorectal cancer.
Data from the American Cancer Society estimate there will be approximately 234,460 new cases of prostate cancer in the US in 2006.
Around 27,350 men are expected to die from the cancer in the US in 2006.
Within 24 hours of the time you read this, around 75 American men will die from the disease.
Prostate cancer is more commonly found in North America and northwestern Europe. It is less common in Africa, Asia, Central and South America.
The data shows that about one in six men will be diagnosed with prostate cancer during his lifetime. The more encouraging news is that only one male in 34 will die of it.
Around 99% of those diagnosed with prostate cancer are still alive in five years, excluding those who died from other causes.
Prostate cancer also appears to have a genetic basis. Men with first-degree relatives with prostate cancer have twice the risk for developing this disease.
Men who are obese (those with a body mass index of over 32.5) are 33% more likely to die from diagnosed prostate cancer.
Individuals who have a diet high in red meat or high-fat dairy products may have a greater chance of developing prostate cancer.
Men over 50 are burdened with most of all prostate cancer diagnosis, with 65% diagnosed after age 65. Therefore, it is recommended that men over 50 years of age begin testing for the disease.
Testing for prostate cancer is done through a PSA blood test and a digital rectal exam. Current widespread screening detects nine out of 10 of these cancers early.
Prostate cancer screening takes less than 10 minutes and is covered by health insurance in many states.
African American men have the highest incidence and mortality rates of prostate cancer in the world. The incidence rate is up to 60% higher while the mortality rate is 2.5 times that of Caucasian males, who have the second highest rate.
Approximately 90% of all prostate cancers are diagnosed at the local and regional stages; the 5-year survival rate for patients whose tumors are diagnosed at these stages approaches 100%.
More than nine out of 10 (92%) of those diagnosed with the cancer survive 10 years while more than six out of 10 (61%) are still alive after 15 years.
The number of prostatectomy procedures performed in the US was 167,000 in 2003, stated the 2003 National Hospital Discharge Survey.
Several billion dollars are spent each year to treat prostate cancer in the US.
During the past 13 years, the Prostate Cancer Foundation has raised more than $260 million to support prostate cancer research. During that same period, US government funding for research has increased 20 times.

Data provided by the American Cancer Society, Prostate Cancer Foundation, and the National Prostate Cancer Coalition.

Symptoms of Prostate Cancer

Indications and Usage
TRELSTAR^® Depot and TRELSTAR^® LA are indicated in the palliative treatment of advanced prostate cancer. TRELSTAR Depot or TRELSTAR LA offer an alternative treatment for prostate cancer when orchiectomy or estrogen administration are either not indicated or unacceptable to the patient.

Safety Information

The most commonly reported adverse events associated with the use of TRELSTAR^® Depot/TRELSTAR^® LA included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%), headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) . TRELSTAR is contraindicated in women who are or may become pregnant as well as patients who are hypersensitive to triptorelin, other LHRH agonists, or LHRH . Infrequent postmarketing reports of anaphylactic shock and angioedema have been received since 1986 (global experience) . As with all LHRH agonists, triptorelin causes an initial transient increase in testosterone levels. Patients may experience the onset or exacerbation of symptoms during this period, including bone pain, neuropathy, hematuria, spinal cord compression, or urethral or bladder outlet obstruction. Patients with metastatic vertebral lesions and/or urinary tract obstruction should be closely observed.